Guanine nucleotide exchange factor VAV2 (VAV2)

Guanine nucleotide exchange factor VAV2 is a cytoplasmic protein encoded by the human VAV2 gene that acts as a guanine nucleotide exchange factor for Rho family GTPases, including RAC1 and Cdc42[1][2]. Unlike VAV1, which is restricted to the hematopoietic system, VAV2 is expressed in various tissues and participates in multiple signaling pathways that control cell proliferation, cytoskeletal organization, and phagocytosis[2][3]. In the immune system, VAV2 modulates activation signals from the T cell receptor and B cell receptor, primarily by activating Cdc42 and RAC1, resulting in effects on calcium entry, integrin-dependent signaling, and actin dynamics[1][2]. Pathologically, VAV2 acts as a proto-oncogene and is overexpressed and phosphorylated in head and neck squamous cell carcinoma, contributing to cancer cell proliferation via downstream pathways including c-MYC and YAP/TAZ/TEAD[3]. There are no approved drugs directly targeting VAV2, but inhibitors of downstream signaling mediators such as Cdc42 have been used experimentally to elucidate its function[1]. Targeting VAV2 therapeutically poses challenges due to its role in normal cell signaling and regeneration as well as its contribution to tumorigenesis[3].

Other names

VAV2VAV-2vav 2 oncogeneguanine nucleotide exchange factor VAV2

Drugs/inhibitors can act by inhibiting downstream GTPases (e.g., Cdc42), thereby blocking VAV2-mediated suppression or promotion of calcium entry and proliferation signaling[1]. No direct VAV2 inhibitor mechanism of action established for approved drugs.